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ABSTRACT
Background  Genome-wide association studies 
(GWAS) have been extremely successful in the search 
for susceptibility risk factors for complex genetic 
autoimmune diseases. As more studies are published, 
evidence is emerging of considerable overlap of loci 
between these diseases. In juvenile idiopathic arthritis 
(JIA), another complex genetic autoimmune disease, the 
strategy of using information from autoimmune disease 
GWAS or candidate gene studies to help in the search 
for novel JIA susceptibility loci has been successful, 
with conﬁ  rmed association with two genes, PTPN22 
and IL2RA. Rheumatoid arthritis (RA) is an autoimmune 
disease that shares similar clinical and pathological 
features with JIA and, therefore, recently identiﬁ  ed 
conﬁ  rmed RA susceptibility loci are also excellent JIA 
candidate loci.
Objective  To determine the overlap of disease 
susceptibility loci for RA and JIA.
Methods  Fifteen single nucleotide polymorphisms 
(SNPs) at nine RA-associated loci were genotyped in 
Caucasian patients with JIA (n=1054) and controls 
(n=3531) and tested for association with JIA. Allele and 
genotype frequencies were compared between cases 
and controls using the genetic analysis software, PLINK.
Results  Two JIA susceptibility loci were identiﬁ  ed, one 
of which was a novel JIA association (STAT4) and the 
second conﬁ  rmed previously published associations of the 
TRAF1/C5 locus with JIA. Weak evidence of association 
of JIA with three additional loci (Chr6q23, KIF5A and 
PRKCQ) was also obtained, which warrants further 
investigation.
Conclusion  All these loci are good candidates in view 
of the known pathogenesis of JIA, as genes within these 
regions (TRAF1, STAT4, TNFAIP3, PRKCQ) are known 
to be involved in T-cell receptor signalling or activation 
pathways.
INTRODUCTION
Complex genetic diseases are caused by the effects 
of multiple genes in combination with lifestyle and 
environmental factors. In the past couple of years, 
with the emergence of genome-wide association 
studies (GWAS), there has been an explosion of 
genetic discoveries for many complex genetic auto-
immune diseases such as Crohn’s disease, type 1 
diabetes, multiple sclerosis and rheumatoid arthri-
tis (RA). Indeed, more genetic risk factors were 
identiﬁ  ed for common diseases in 2007 than had 
been collectively reported before that date.1 It is 
also interesting to note that evaluating the results 
from the study of one disease in other complex 
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diseases can disclose common risk factors.1 Thus 
there has been detectable overlap of loci for auto-
immune diseases, with examples such as a region 
on chromosome 4q27 that encodes the interleukin 
2 (IL2) and IL21 genes, which is associated with 
susceptibility to coeliac disease, multiple sclerosis, 
type 1 diabetes and RA,2 3 and the IL23R region on 
1p31 which has been associated with Crohn’s dis-
ease,4 ulcerative colitis,4 psoriasis5 and ankylosing 
spondylitis.6
Juvenile idiopathic arthritis (JIA), another com-
plex genetic autoimmune disease, is the most com-
mon chronic inﬂ   ammatory rheumatic disease in 
children and is an important cause of short- and 
long-term disability.7 It is deﬁ   ned as arthritis of 
unknown aetiology that starts before the age of 
16 and persists for at least 6 weeks. JIA can be 
subdivided into seven clinically more homoge-
neous subtypes, using the International League of 
Associations for Rheumatology (ILAR) classiﬁ  ca-
tion system.8 As in other autoimmune diseases 
there are well-established associations of the HLA 
region with JIA.9
In JIA, only a single, comparatively small 100k 
single nucleotide polymorphism (SNP) study has 
been published to date.10 This is largely owing to 
the low prevalence and clinically heterogeneous 
nature of JIA, meaning that collection of sufﬁ  ciently 
large and thus powerful, sample sizes has been pro-
tracted compared with other complex autoimmune 
diseases. However, this does not mean that data 
from GWAS cannot be exploited to help elucidate 
the underlying genetic basis of this disease. Indeed, 
the strategy of using information from autoimmune 
disease GWAS or candidate studies to help identify 
JIA susceptibility genes has already been successful 
in identifying two JIA susceptibility genes, protein 
tyrosine phosphatase non-receptor 22 (PTPN22)11 
and more recently, IL2RA,12 which have been vali-
dated in independent cohorts.
RA is an autoimmune disease that has similar 
clinical and pathological features to those of JIA. 
In the past year a number of novel RA suscepti-
bility genes have been identiﬁ  ed, which have been 
conﬁ  rmed in independent datasets, including the 
STAT4 gene,13 14 the TRAF1 and C5 region on chro-
mosome 9,14–16 a region on chromosome 6q23,17 18 
the KIF5A gene,19 a region on chromosome 10p15 
close to the PRKCQ gene,19 MMEL,19 20 CD40,20 
CDK620 and a region on chromosome 9p13 close to 
the CCL21 gene.20 Thus, these loci are also excel-
lent JIA candidate susceptibility loci and, therefore, 
the aim of this study was to determine whether 
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these conﬁ  rmed that RA susceptibility loci are also associated 
with susceptibility to JIA.
SUBJECTS AND METHODS
Subjects
DNA was available for 1054 UK Caucasian patients with JIA 
(332 male, 715 female) from three sources: the British Society 
for Paediatric and Adolescent Rheumatology (BSPAR) National 
Repository of JIA (n=654); a cohort of UK Caucasian patients 
with longstanding JIA (n=201), described previously21; and a third 
cohort collected as part of the Childhood Arthritis Prospective 
Study (CAPS), a prospective inception cohort study of JIA cases 
from ﬁ  ve centres across the UK (n=199).22 JIA cases were classi-
ﬁ  ed according to ILAR criteria,23 which are a combined set of all 
ILAR subtypes (online supplementary table 1).
Healthy Caucasian control DNA samples were available from 
ﬁ  ve centres in the UK as described previously17: Manchester, 832 
controls (including 228 1958 birth cohort controls); Shefﬁ  eld, 929 
controls; Leeds, 422 controls; Aberdeen, 825 controls; Oxford, 
523 controls, total control sample size=3531). All individuals 
were recruited with ethical approval and provided informed 
consent (North-West Multi-Centre Research Ethics Committee 
(MREC 99/8/84) and the University of Manchester Committee 
on the Ethics of Research on Human Beings).
SNP selection
In total, 15 SNPs were selected for genotyping in nine indepen-
dent genetic regions, all of which have robust conﬁ  rmed evi-
dence for association with RA. These comprised:
STAT4: Four SNPs (rs11889341, rs7574865, rs8179673 and 
rs10181656) located in the third intron of STAT4, which showed 
the strongest association with North American and Swedish RA 
cases13; Korean RA cases24 were also selected.
TRAF1/C5: Three SNPs located in the TRAF1/C5 region were 
identiﬁ  ed for investigation, one of which (rs10818488) showed 
the strongest evidence for association with Dutch RA   cases.15 
The other two SNPs, rs3761847 and rs2900180, showed the 
strongest evidence for association in North American and 
Swedish RA cases.16 
6q23: rs6920220 and rs13207033, located at the chromosome 
6q23 RA susceptibility locus, were also investigated. The SNPs 
lie in an intergenic region between OLIG3 and TNFAIP3. Variants 
in this region have been reported to be independently associated 
with RA risk.17 18 The minor allele of rs6920220 is associated 
with increased risk of RA (minor allele frequency (MAF) cases > 
controls), whereas the minor allele of rs10499194 is associated 
with protection (MAF controls > cases). Although the latter was 
not directly genotyped, a perfect proxy SNP (rs13207033; r2=1) 
was.
KIF5A: Association with rs1678542, which maps to intron 15 
of the KIF5A gene on chromosome 12q13 was initially identi-
ﬁ  ed in the Wellcome Trust case–control consortium (WTCCC) 
genome-wide association screen of RA cases and controls25 and 
then validated in an independent cohort.19
PRKCQ: rs4750316 maps to an intergenic region on chro-
mosome 10p15, the closest gene, PRKCQ, being 76 kb away. 
Association with this SNP has been validated in independent 
datasets.19 20
MMEL: Association with rs10910099, which maps to intron 11 
of the MMEL (membrane metallo-endopeptidase-like 1) gene 
on chromosome 1p36 was initially identiﬁ  ed in the WTCCC 
genome-wide association screen of RA cases and controls25 and 
then validated in an independent cohort.19
CD40: Association of rs4810485 on chromosome 20q13 with 
RA was reported in a meta-analysis of two published GWAS. 
The SNP lies in intron 2 of the CD40 gene.20
CCL21: rs2812378, which maps to chromosome 9p13, is situ-
ated ~0.1 kb from the CCL21 gene. Association of this SNP with 
RA was also reported in the meta-analysis of two published 
GWAS.20
CDK6: rs42041, which maps to chromosome 7q21, lies within 
intron 7 of the cyclin-dependent kinase 6 gene. Association of 
this SNP with RA was also reported in the meta-analysis of two 
published GWAS.20
Genotyping
All SNPs were genotyped in UK JIA cases and controls. 
Genotyping was performed using the Sequenom iPLEX platform. 
A 90% sample quality control rate and 90% SNP   genotyping 
success rate was imposed on the analysis. The control genotype 
data have been reported previously.14 17 19
Statistical analysis
Genotype and allele frequencies were compared between cases 
with JIA and controls using STATA version 9 SE (StataCorp, 
Texas, USA) and PLINK.26 Associations were expressed as two-
sided p values, allelic odds ratios (ORs) and their 95%  CIs. Power 
calculations were performed using Quanto based on   previous 
RA studies for these SNPs.14 17–19 JIA is a phenotypically het-
erogeneous disease and can be classiﬁ  ed into more clinically 
  homogeneous diseases using the ILAR classiﬁ  cation criteria.8 
However, comparing each of the ILAR subtypes separately 
against controls would result in a large number of hypothesis 
tests. Therefore we ﬁ  rst examined whether there was evidence 
of a difference in allele frequencies between the seven ILAR 
subtypes. Differences between subtypes were assessed using 
χ2 tests on the 7×2 tables. Only when a difference was found 
(p<0.05) were separate ORs and 95% CIs calculated for the 
subgroups.
Table 1  Power calculations for the JIA study
SNP Locus
Allele 
frequency
Effect 
size (OR)
Power of JIA 
study (%)*
rs10910099†,‡ MMEL 0.66 0.9 53
rs11889341§ STAT4 0.22 1.12 48
rs7574865§ STAT4 0.22 1.17 76
rs8179673§ STAT4 0.22 1.13 55
rs10181656§ STAT4 0.22 1.13 55
rs13207033¶ TNFAIP3 0.79 0.86 67
rs6920220‡ TNFAIP3 0.22 1.22 93
rs42041** CDK6 0.24 1.15 69
rs3761847§ TRAF1 0.43 1.11 55
rs10818488§ TRAF1 0.43 1.12 62
rs2900180§ TRAF1 0.35 1.17 86
rs2812378** CCL21 0.34 1.12 59
rs4750316‡ PRKCQ 0.80 0.85 72
rs1678542‡ KIF5A 0.63 0.88 69
rs4810485** CD40 0.75 0.84 84
Sample size, 1054 JIA cases and 3531 controls.
*At α value 0.05, assuming a log-additive model; †SNP in r2=0.95 with the SNP 
associated with RA in the WTCCC study; ‡Barton et al (2008)19; §Barton et al (2008)14; 
**Raychaudhuri et al (2008)20; ¶Orozco et al (2009) (submitted).
JIA, juvenile idiopathic arthritis; OR, odds ratio; RA, rheumatoid arthritis; SNP, single 
nucleotide polymorphism.
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DISCUSSION
In this study we examined nine recently identiﬁ   ed RA loci, 
which have been conﬁ  rmed in independent datasets, for asso-
ciation with JIA. Using this approach we have identiﬁ  ed two 
JIA susceptibility loci, of which one was a novel JIA association 
(STAT4); while the evidence for a true association for STAT4 is 
compelling, it will require validation in independent JIA case–
control cohorts, to conﬁ  rm it as a JIA susceptibility locus. The 
second association conﬁ  rms previously published associations 
of the TRAF1/C5 locus with JIA susceptibility.27 28 However, 
previous studies of this locus have provided conﬂ  icting evidence 
for association. For example, a recent study of Dutch JIA cases 
and controls investigated the rs10818488 SNP in the TRAF1/C5 
region,27 and found no evidence for association of this SNP in 
patients with JIA as a whole. Interestingly, in our UK study we 
also found no statistically signiﬁ  cant evidence for association of 
this SNP in all JIA cases but there was a trend (allelic OR=1.09, 
95% CI 0.98 to 1.21, trend p=0.1).
We performed a meta-analysis of the two studies which yielded 
signiﬁ  cant evidence for association (OR=1.09, 95% CI 1.0 to 1.2, 
p=0.05) with no evidence for heterogeneity between the two 
cohorts (p=0.9). A second, small study of SNPs within TRAF1/
C5 region in USA JIA cases also reported association with this 
region. The strongest effect in that study was with rs376187.28 
This SNP was not associated in our current study, although 
there was association with another SNP (rs2900180). The lack 
of consistency between studies of TRAF1/C5 region and JIA sus-
ceptibility may be due to the lack of power of individual studies 
to detect the modest effect sizes reported at this locus. For the 
three SNPs in this study in the TRAF1/C5 region we had 86% 
power to detect an effect for the SNP rs2900180 and we found 
that this was the most strongly associated SNP with JIA for this 
region. For the other two SNPs we had ~60% power to detect 
an association and therefore the lack of association may be a 
false-negative result due to small sample size. This is also com-
pounded by the fact that, as yet, the causal SNP(s) in this region 
has not been determined.
Although not statistically signiﬁ  cant, we found weak evidence 
of association with JIA of SNPs in the chromosome 6q23 region, 
within KIF5A and close to PRKCQ; in each case the effect sizes 
were similar to those seen in RA. Thus, given the relatively low 
RESULTS
Fifteen SNPs across nine loci were genotyped in JIA cases (n=1054) 
and controls (n=3531) and analysed for association with JIA.
Table 1 shows the power of this study to detect the effect 
sizes identiﬁ  ed in the RA studies for these SNPs, at a 5% signiﬁ  -
cance level, assuming a log-additive model. As expected, despite 
being the largest collection of JIA cases and controls investigated 
to date, for many of the SNPs this study had modest power to 
detect an effect. A Bonferroni correction of 15 was applied to 
correct for the number of SNPs studied, resulting in a p value 
threshold of 0.003 for claims of signiﬁ  cance.
Despite the modest power in this study, all of the four STAT4 
SNPs were associated with JIA, with the strongest association for 
rs8179673 (allelic OR=1.25, 95% CI 1.11 to 1.4, trend p=0.0002) 
(table 2). These SNPs are in strong linkage disequilibrium with 
each other (r2>0.96). One of the three TRAF1/C5 SNPs was sig-
niﬁ  cantly associated with JIA, rs2900180 (allelic OR=1.21, 95% 
CI 1.09 to 1.35, trend p=0.0003). The associated SNP was the 
one for which the sample size tested had most power to detect 
statistical evidence for association.
The chromosome 6q23 SNP, rs6920220, also showed weak 
association with JIA (allelic OR=1.16, 95% CI 1.02 to 1.31, trend 
p=0.02) (table 2). As with RA, the SNP, rs13207033, showed a 
weak protective association with JIA (allelic OR=0.87, 95% CI 
0.77 to 0.98, trend p=0.02). Both the KIF5A SNP, rs1678542 and 
the SNP, rs4750316, close to PRKCQ, showed weak protective 
association with JIA (allelic OR=0.91, 95% CI 0.82 to 1.01, trend 
p=0.08 and allelic OR=0.88, 95% CI 0.77 to 1.0, trend p=0.05, 
respectively), although the evidence for association did not reach 
the corrected threshold for any of these loci.
The markers rs10910099 in the MMEL gene, rs42041 in the 
CDK6 gene, rs4810485 in the CD40 gene and rs2812378, close 
to the CCL21 gene, showed no association with JIA (table 2).
The associated SNPs were examined for differences in allele 
frequencies between the seven ILAR subtypes. In all cases this 
was not signiﬁ  cant (p>0.05) (data not shown). Therefore further 
stratiﬁ  cation by ILAR subtype was not performed.
Figure 1 shows a comparison between the association analysis 
results in RA and JIA. For all the JIA-associated SNPs the same 
allele is associated with JIA as was associated with RA and effect 
sizes are similar.
Table 2  Association analysis in JIA cases and controls of SNPs previously associated with RA
Marker Chromosome Locus
HWE 
controls
MAF 
cases
MAF 
controls Genotype frequency cases (%) Genotype frequency controls (%)
Trend 
p value
Allelic OR 
(95% CI)
rs10910099 1 MMEL 0.27 0.34 0.33 90 (10.3) 412 (47.2) 371 (42.5) 401 (11.0) 1572 (43.1) 1672 (45.9) 0.28 1.06 (0.95 to 1.19)
rs11889341 2 STAT4 0.69 0.26 0.22 54 (5.7) 376 (54.4) 512 (54.4) 162 (4.6) 1200 (34.4) 2125 (60.9) 0.0004 1.24 (1.1 to 1.39)
rs7574865 2 STAT4 0.62 0.26 0.22 52 (5.5) 378 (40.1) 513 (54.4) 161 (4.6) 1208 (34.3) 2151 (61.1) 0.0004 1.24 (1.1 to 1.39)
rs8179673 2 STAT4 0.62 0.26 0.22 55 (5.9) 378 (40.2) 507 (53.9) 162 (4.7) 1198 (34.6) 2103 (60.7) 0.0002 1.25 (1.11 to 1.4)
rs10181656 2 STAT4 0.52 0.26 0.22 54 (5.7) 377 (40.1) 509 (54.1) 159 (4.6) 1200 (34.5) 2115 (60.9) 0.0002 1.24 (1.11 to 1.4)
rs6920220 6 6q23/
TNFAIP3
0.04 0.24 0.21 57 (6.5) 297 (34.0) 519 (59.5) 140 (3.8) 1251 (34.3) 2253 (61.8) 0.02 1.16 (1.02 
to 1.31)
rs13207033 6 6q23/
TNFAIP3
0.5 0.25 0.28 64 (7.1) 327 (36.3) 511 (56.7) 229 (7.6) 1237 (40.8) 1563 (51.6) 0.02 0.87 (0.77 
to 0.98)
rs42041 7 CDK6 0.66 0.26 0.25 65 (7.0) 347 (37.5) 514 (55.5) 182 (6.1) 1125 (38.0) 1655 (55.9) 0.59 1.03 (0.92 to 1.16)
rs3761847 9 TRAF1/C5 0.39 0.44 0.43 199 (21.1) 438 (46.5) 305 (32.4) 607 (18.8) 1557 (48.2) 1063 (33.0) 0.27 1.06 (0.96 to 1.18)
rs10818488 9 TRAF1/C5 0.81 0.45 0.43 201 (21.3) 451 (47.8) 291 (30.9) 645 (18.5) 1721 (49.3) 1126 (32.2) 0.1 1.09 (0.98 to 1.21)
rs2900180 9 TRAF1/C5 0.97 0.39 0.35 149 (15.8) 437 (46.4) 356 (37.8) 407 (11.9) 1548 (45.3) 1464 (42.8) 0.0003 1.21 (1.09 
to 1.35)
rs2812378 9 CCL21 0.30 0.33 0.35 88 (9.5) 433 (46.5) 410 (44.0) 377 (12.5) 1339 (44.5) 1294 (43.0) 0.1 0.91 (0.82 to 1.02)
rs4750316 10 PRKCQ 0.91 0.18 0.2 38 (4.0) 256 (27.2) 649 (68.8) 133 (3.8) 1106 (31.6) 2261 (64.6) 0.05 0.88 (0.77 to 1.0)
rs1678542 12 KIF5A 0.39 0.35 0.37 109 (11.6) 438 (46.5) 394 (41.9) 497 (14.1) 1622 (45.9) 1411 (40.0) 0.08 0.91 (0.82 to 1.01)
rs4810485 20 CD40 0.05 0.26 0.25 64 (6.9) 351 (37.9) 512 (55.2) 173 (5.7) 1189 (39.1) 1681 (55.2) 0.59 1.03 (0.92 to 1.16)
SNPs with a trend p value <0.05 are highlighted in bold.
HWE, Hardy–Weinberg equilibrium; JIA, juvenile idiopathic arthritis; MAF, minor allele frequency; OR, odds ratio; SNP, single nucleotide polymorphism.
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power within our study, they warrant further investigation in 
independent datasets.
We found no signiﬁ  cant association with the SNPs in the MMEL, 
CDK6, CCL21 or the CD40 genes, which may suggest that these 
genes are RA-speciﬁ  c loci. However, as the effect sizes for these 
genes in RA were modest, this study had limited power to detect 
an association with JIA and MMEL, CDK6 and CCL21 (53%, 69% 
and 59% respectively). For three of these SNPs, the direction of 
association was opposite in the JIA samples compared with the 
RA studies. Larger datasets and meta-analyses will be required to 
completely rule out association of these SNPs with JIA.
One limitation of the study may be the use of a common set 
of controls between this study and two of the previous RA vali-
dation studies.17 19 This is a conventional strategy, as used by the 
WTCCC GWAS,25 to minimise genotyping, but it may be a con-
cern.29 All the control genotypes used in this study were com-
pared with the control data from the WTCCC and there was 
no signiﬁ  cant difference (p<0.05) in the frequencies, suggesting 
these controls accurately represent UK population frequencies.
It is interesting to note that for the JIA susceptibility loci iden-
tiﬁ  ed, the associated allele is the same and effect size similar to 
that seen in studies of RA (ﬁ  gure 1).
This ﬁ  nding, combined with data from previous studies,30 31 
suggests that for many complex diseases there will be some 
shared susceptibility loci while others will be disease speciﬁ  c. 
In JIA, given the clinical heterogeneity, the picture may be 
even more complicated. Current classiﬁ   cation criteria divide 
JIA into seven subgroups and it would be interesting to deter-
mine whether the susceptibility loci identiﬁ  ed are common to 
all subgroups or restricted to only some subgroups. However, 
stratiﬁ  ed analysis leads to small sample sizes for many of the 
subgroups as well as introducing the problem of multiple test-
ing and thus makes interpreting these results challenging. In 
our study, we tested whether there was an overall difference 
in allele frequency between the seven subgroups for each SNP; 
as no SNPs showed a signiﬁ  cant difference between subgroups, 
further stratiﬁ  cation analysis was not undertaken. This lack of 
difference between subgroups may reﬂ  ect our hypothesis/strat-
egy, in that we are looking for shared autoimmune or inﬂ  amma-
tory arthritis susceptibility loci. Alternatively, as already stated, 
the study may have been simply underpowered to detect any 
differences between subgroups. As and when these ﬁ  ndings are 
validated in other cohorts it will be important to combine data 
in order to improve power and accurately determine whether 
the associations seen are consistent between the different clini-
cal subgroups of JIA.
In RA, there is some evidence to suggest that there are dis-
tinct genetic risk factors for anti-cyclic citrullinated peptide 
(anti-CCP)-positive and anti-CCP-negative disease. In the UK 
population the TRAF1/C5 association did appear stronger in the 
anti-CCP- positive subgroup than in the negative subgroup,14 
however, the strength of association of the STAT4 locus was 
similar in both subgroups. There is little evidence for anti-CCP 
antibodies in JIA, apart from in the rheumatoid factor-positive 
polyarthritis subgroup, though antinuclear antibodies (ANA) are 
often observed. However, larger sample sizes will be required 
to investigate any speciﬁ  c associations with ANA-positive and 
ANA-negative subgroups.
It is important to note that for all these loci the causal vari-
ant, indeed in some cases the gene, has yet to be determined. 
Re-sequencing and ﬁ  ne-mapping studies are underway in order 
to further characterise the genetic effects before functional stud-
ies can be undertaken. However, all these loci represent good 
candidates for JIA as genes within these regions (TRAF1, STAT4, 
TNFAIP3, PRKCQ) known to be involved in T-cell receptor sig-
nalling or T-cell activation pathways.
In conclusion, by investigating the overlapping of RA and JIA 
susceptibility loci, we have identiﬁ  ed a novel JIA susceptibility 
locus (STAT4) and conﬁ  rmed association with a second, TRAF1/
C5. It is clear that this strategy is useful in identifying autoim-
mune/arthritis-associated JIA susceptibility loci. However, it is 
likely that there are many more JIA-speciﬁ  c or JIA-subgroup-
speciﬁ  c genes yet to be identiﬁ  ed and well-powered GWAS will 
be required to identify these.
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